Nanox AI Scales Bone Density Software via UK and 3DR Labs Deals
The medical imaging firm is expanding the reach of its HealthOST AI software through new distribution agreements in the United Kingdom and with 3DR Labs.
Nanox AI has entered into a series of distribution and reseller agreements to expand the availability of its HealthOST software. The move signals a strategic push to integrate AI-driven diagnostic tools into broader clinical workflows across multiple markets.
HealthOST is an AI-based software designed to analyze CT images of the spine to detect low bone mineral density. By automating the identification of bone loss, the tool aims to streamline the screening process for osteoporosis and other metabolic bone diseases. To scale this technology, Nanox AI has secured two primary partnerships: an exclusive sales reseller agreement with Vertec Scientific for the United Kingdom market, covering an initial three-year term, and a collaboration with 3DR Labs, which is integrating HealthOST—alongside HealthCCSng and HealthFLD—into its existing imaging services portfolio.
The Shift Toward AI Screening
This expansion comes as the healthcare industry increasingly adopts opportunistic screening. Traditionally, bone density is measured via Dual-energy X-ray Absorptiometry (DXA) scans. However, AI tools like HealthOST allow clinicians to extract critical bone density data from standard CT scans that were originally performed for other reasons. This capability transforms routine imaging into a dual-purpose diagnostic event, potentially identifying high-risk patients who would otherwise remain unscreened.
Market Implications
For the medical imaging market, these distribution deals reduce the friction associated with deploying specialized AI software. By partnering with established entities like Vertec Scientific and 3DR Labs, Nanox AI bypasses the need to build independent sales infrastructures in every region. This model accelerates the adoption of AI-enhanced healthcare tools, shifting the burden of distribution to partners who already possess deep relationships with radiology clinics and hospitals.
Future Outlook
As Nanox AI continues to integrate its suite of tools—including the HealthCCSng and HealthFLD software—into partner portfolios, the focus will likely shift toward clinical outcomes and the rate of early detection. While the UK agreement provides a stable three-year foothold in Europe, the long-term success of the strategy depends on how effectively these partners can embed the software into standard radiology billing and reporting cycles. Observers will be watching for further international reseller agreements as the company seeks to globalize its AI diagnostic footprint.